Optimi Health Corp
OTCQX International:OPTHFView on Canadian Exchange

  • LAST PRICE
    0.1469
  • TODAY'S CHANGE (%)
    -0.0003 (-0.2038%)
  • Bid / Lots
    0.1442/ 305
  • Ask / Lots
    0.1520/ 50
  • Open / Previous Close
    0.1460 / 0.1472
  • Day Range
    0.1400
    0.1469
  • 52 Week Range
    0.1100
    0.4300
  • Volume
    3,540

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 23, 2024

      Show headlines and story abstract

    • 7:32AM ET on Wednesday Oct 23, 2024 by Dow Jones
      Companies Mentioned: OPTI

      Vancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in botanical psilocybin and MDMA, is proud to announce that the first group of patients with post-traumatic stress disorder (PTSD) in Australia has successfully received treatment with its GMP-certified MDMA capsules under the Authorised Prescriber Scheme. In response to growing demand, the Company has received an additional order for 700 doses after its initial shipment of 160 doses was fully allocated in under eight weeks.

    • 7:31AM ET on Wednesday Oct 23, 2024 by Newsfile
      Companies Mentioned: OPTHF

      Vancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in botanical psilocybin and MDMA, is proud to announce that the first group of patients with post-traumatic stress disorder (PTSD) in Australia has successfully received treatment with its GMP-certified MDMA capsules under the Authorised Prescriber Scheme. In response to growing demand, the Company has received an additional order for 700 doses after its initial shipment of 160 doses was fully allocated in under eight weeks.

Peers Headlines

No documents available